Selux Diagnostics is developing a Next-Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital-acquired infections, and help combat the global antibiotic resistance epidemic. 

Biotechnology

Selux Diagnostics

Selux Diagnostics' headquarters in Boston, MA, United States

Steve Lufkin

Description

People (9)

Steve Lufkin

Jack Percoskie

Kassi Cox Whale, MBA

Anika Hansen

Mikaela Metzendorf

Zachary Andersen

Eric Bewig

Matthew Cyrus

Brett Mooney

Jobs (1)

Engineering Intern